Quick Answer
The SURPASS-CVOT trial of 13,000+ patients found Mounjaro (tirzepatide) cut cardiovascular death risk by 62% and outperformed older GLP-1 drug dulaglutide — a breakthrough for Indian diabetics with heart disease.
Free Consultation
Have questions about GLP-1 Therapy?
Enter your phone number — a specialist calls you back in 30 minutes. Free, no commitment.
🔒 Confidential · No spam · 10,000+ patients helped
If you have type 2 diabetes and are concerned about heart disease — or if you already have a diagnosis of cardiovascular disease — important new evidence has emerged that could directly affect your treatment decisions. The results of the SURPASS-CVOT trial, one of the largest and longest cardiovascular outcome studies ever conducted for a GLP-1 drug, show that Mounjaro (tirzepatide) dramatically reduces the risk of major heart events including cardiovascular death. For Indian patients, where diabetes and heart disease frequently coexist and often prove fatal, this research represents a genuine turning point.
What Is Mounjaro and How Is It Different From Other GLP-1 Drugs?
Mounjaro, known by its generic name tirzepatide, is a dual-action medication that works on two receptors simultaneously — the GLP-1 receptor and the GIP receptor. This dual mechanism is what sets it apart from earlier GLP-1 drugs like semaglutide (Ozempic, Wegovy) or dulaglutide (Trulicity), which target only the GLP-1 receptor. By activating both pathways, Mounjaro produces stronger effects on blood sugar control, appetite reduction, and weight loss than any single-target GLP-1 drug.
Manufactured by Eli Lilly, Mounjaro is approved in India for the treatment of type 2 diabetes and obesity. Its sister brand Zepbound carries the same active compound and is approved specifically for weight loss. In India, Mounjaro has been available for adults with type 2 diabetes, and with the growing awareness of GLP-1 therapies following the semaglutide patent expiry in 2026, more Indian patients and doctors are exploring it as a treatment option.
What the SURPASS-CVOT Trial Found
The SURPASS-CVOT trial is a Phase 3 cardiovascular outcomes study conducted by Eli Lilly, comparing Mounjaro head-to-head against dulaglutide (sold as Trulicity) — previously considered one of the better GLP-1 drugs for cardiovascular protection. The trial enrolled more than 13,000 adults across 30 countries over more than four and a half years, making it the largest and longest study of tirzepatide ever conducted.
Free Consultation
Have questions about GLP-1 Therapy?
Enter your phone number — a specialist calls you back in 30 minutes. Free, no commitment.
🔒 Confidential · No spam · 10,000+ patients helped
All participants in the trial had type 2 diabetes and established atherosclerotic cardiovascular disease — meaning they had documented heart disease such as prior heart attack, prior stroke, or blocked arteries. This is exactly the population at highest cardiovascular risk.
The results were striking. Mounjaro achieved the primary endpoint by demonstrating non-inferiority to dulaglutide for major adverse cardiovascular events (MACE-3), which include cardiovascular death, heart attack, and stroke. But the trial results went significantly further. A separate analysis, highlighted by Healthline, found that patients on Mounjaro had a 62 percent lower risk of cardiovascular death specifically compared to those on dulaglutide. Additionally, Mounjaro patients showed significantly better outcomes on A1C reduction (blood sugar control), weight loss, renal function, and all-cause mortality compared to those on dulaglutide. Essentially, in a head-to-head trial against an already proven cardiovascular GLP-1 drug, Mounjaro won across nearly every important measure.
Why This Is Critical for Indian Patients
India bears one of the heaviest burdens of diabetes and cardiovascular disease in the world. Approximately 77 million Indian adults have type 2 diabetes, and that number is projected to rise further. Crucially, the combination of diabetes and heart disease is extraordinarily common in India — and extraordinarily deadly. Cardiovascular disease remains the leading cause of death among people with diabetes globally, and Indian patients develop heart disease at younger ages and at lower body weights than Western populations.
The biological reasons are well-documented. South Asians tend to have higher insulin resistance, more visceral fat (fat around internal organs), and a genetic predisposition toward early artery disease — even at BMIs that Western guidelines would consider normal. An Indian man with a BMI of 26 and type 2 diabetes already carries a cardiovascular risk profile that demands aggressive treatment. When heart disease is added on top, the mortality risk climbs steeply.
For these patients, the SURPASS-CVOT results matter enormously. A 62 percent reduction in cardiovascular death compared to an already-good GLP-1 drug is not a marginal gain. It is a potentially life-saving advantage. Combined with Mounjaro's superior blood sugar lowering and weight loss effects, the trial makes a strong case that for Indian patients with both diabetes and established heart disease, Mounjaro may now be the most evidence-backed GLP-1 therapy available.
Free Consultation
Have questions about GLP-1 Therapy?
Enter your phone number — a specialist calls you back in 30 minutes. Free, no commitment.
🔒 Confidential · No spam · 10,000+ patients helped
How Tirzepatide Protects the Heart
The cardiovascular benefits of Mounjaro likely come from multiple overlapping mechanisms. Like other GLP-1 drugs, it reduces blood sugar, blood pressure, inflammation, and body weight — all of which independently lower cardiovascular risk. But the addition of the GIP receptor activation appears to do something extra. GIP receptors are present in the heart and blood vessels, and activating them may improve how efficiently the heart uses energy, reduce inflammation in arterial walls, and protect cardiac muscle cells from injury. Weight loss from Mounjaro is also considerably greater than from single-target GLP-1 drugs, and greater weight loss translates to greater reductions in visceral fat, blood pressure, and metabolic stress on the cardiovascular system.
Researchers at SCAI 2026 (the Society for Cardiovascular Angiography and Interventions) also presented two new studies showing that tirzepatide reduced heart-related risks specifically in patients undergoing percutaneous coronary intervention (angioplasty) and in obese patients having heart valve surgery. These findings extend the protective signal beyond general diabetic populations into some of the highest-risk cardiac patients imaginable.
What This Means If You Are on a GLP-1 Drug in India
If you are currently taking a semaglutide-based medication — Ozempic, Wegovy, or an Indian generic — for diabetes or weight management, you are already benefiting from meaningful cardiovascular protection. Semaglutide has its own robust cardiovascular trial evidence. However, if you have established heart disease or are at very high cardiovascular risk, the SURPASS-CVOT data gives you a strong reason to ask your doctor whether switching to or starting Mounjaro might offer additional benefit.
If you have been told you have diabetes and heart disease and are not yet on any GLP-1 medication, this trial is one of the most important pieces of clinical evidence you can bring to your doctor. The combination of cardiovascular protection, blood sugar lowering, and weight loss in a single weekly injection makes Mounjaro a uniquely powerful option for your risk profile.
Free Consultation
Have questions about GLP-1 Therapy?
Enter your phone number — a specialist calls you back in 30 minutes. Free, no commitment.
🔒 Confidential · No spam · 10,000+ patients helped
GLP-1 medications including Mounjaro must be started and monitored under proper medical supervision. They are not suitable for everyone — patients with certain thyroid conditions, pancreatitis history, or kidney disease require careful evaluation first. Cost also matters: Mounjaro is generally more expensive than semaglutide generics, and access varies. A GLP-1 specialist can assess your full clinical picture and guide the most appropriate treatment plan for your situation.
Call MySurgery at 8588967050 or WhatsApp us to speak with a GLP-1 specialist. Free consultation, callback in 30 minutes.
Disclaimer: This article is based on information published on the referenced websites below and is intended for general awareness only. It is not a substitute for professional medical advice.
References: 1. Eli Lilly Investor Relations (SURPASS-CVOT results) — https://investor.lilly.com/news-releases/news-release-details/lillys-mounjaro-tirzepatide-gipglp-1-dual-agonist-demonstrated 2. Healthline — https://www.healthline.com/health-news/tirzepatide-reduces-risk-major-cardiovascular-events 3. American Society for Preventive Cardiology — https://www.aspconline.org/news/lillys-mounjaro-tirzepatide-a-gipglp-1-dual-agonist-demonstrated-cardiovascular-protection
MySurgery GLP-1 Team
GLP-1 Research & Patient Education
Have questions about GLP-1 Therapy?
Free consultation. Expert doctors. Callback in 30 minutes.